Unicycive Therapeutics, Inc.

UNCY

US90466Y1038

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-17 pm EDT			5-day change	1st Jan Change
0.6867 ^USD	-8.96%		-23.70%	-13.54%

Jun. 17	Unicycive Therapeutics to Implement 1-for-10 Reverse Stock Split	MT
Jun. 17	Unicycive Therapeutics Announces Reverse Stock Split	RE

Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia

Published on 06/10/2025 at 06:34

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Unicycive Therapeutics, Inc.

Unicycive Therapeutics to Implement 1-for-10 Reverse Stock Split	Jun. 17	MT
Unicycive Therapeutics Announces Reverse Stock Split	Jun. 17	RE
Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application	Jun. 10	DJ
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis	Jun. 10	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	Jun. 10	MT
Top Premarket Decliners	Jun. 10	MT
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday Amid US-China Trade Optimism	Jun. 10	MT
Unicycive Says US FDA Inspection Reveals Manufacturing Deficiencies for Oxylanthanum Carbonate Drug Candidate; Shares Down	Jun. 10	MT
Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia	Jun. 10	RE
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 14	CI
Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target	Apr. 21	MT
Unicycive Therapeutics, Inc. Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Patients with Hyperphosphatemia on Dialysis	Apr. 10	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 31	CI
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360	Feb. 20	CI
Unicycive Therapeutics, Inc. Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science	Jan. 28	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 13	CI
Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate	Nov. 11	MT
Unicycive : FDA to Review Lead Drug Candidate for Hyperphosphatemia	Nov. 11	DJ
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis	Nov. 11	CI
Maxim Adjusts Price Target on Unicycive Therapeutics to $2 From $4, Maintains Buy Rating	24-09-06	MT
Unicycive Therapeutics Announces Submission of the New Drug Application to the U.S. FDA for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis	24-09-03	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
Unicycive Therapeutics Receives US Patent for Potential Acute Kidney Treatment	24-07-17	MT
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate	24-07-10	CI
Unicycive Therapeutics Files Shelf Registration for Sale of Up to 50 Million Shares by Stockholders	24-07-05	MT

Chart Unicycive Therapeutics, Inc.

Duration

Period

UNCY: Dynamic Chart

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Employees

Sector

Biotechnology & Medical Research

Calendar

Aug. 17 - Q2 2025 Earnings Release (Projected)

More about the company